drugset / Trial / NCT06253845

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

NCT06253845

Phase 1 Active not recruiting 20 enrolled H. Lee Moffitt Cancer Center and Research Institute
NaSingle-groupOpen-labelTreatment

Summary

Investigators will evaluate the safety of CG0070 for the treatment of patients with Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC).

Timeline

Start
2024-03-01
Primary completion
2027-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cretostimogene Grenadenorepvec Unknown 1e+12 unknown Other